MaxCyte Regulatory News (MXCT)

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notification of Annual General Meeting

Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), along with the Annual Meeting Proxy Card and Form of Direction, has been circulated to Shareholders.

These documents are also available in electronic form on the Company's website: www.maxcyte.com.

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. EDT on 31 October 2018 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA™ therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 For more information, visit www.maxcyte.com.

###

For further information, please contact: